As of last month, breaking news spread across the nation of the first official FDA approved CBD pharmaceutical drug. The FDA is the largest voice behind safe, effective, government-approved medication in the United States, making their authoritative stance powerful in many regards. Due to the FDA approval of Epidiolex, a pharmaceutical drug derived from the CBD compound that’s been proven to reduce seizures in children with Lennox-Gastaut syndrome and Dravet syndrome, the DEA has been forced to reschedule CBDs.
The Benefits of Rescheduling CBDs from Schedule I to Schedule II or III
Now that the FDA has approved and considers Epidiolex a safe and effective treatment for these rare forms of epilepsy, the DEA is forced to downgrade CBDs from Schedule I to Schedule II or III under the DEA’s Controlled Substances Act. This rescheduling must take place within 90 days from the date that the FDA admitted that CBDs have medicinal qualities. The US government has considered marijuana plants to be a gateway drug for several decades now but this recent development has forced the DEA to reschedule CBDs in the same category as Adderall and opioid medication that offer some medicinal value. This rescheduling will hopefully lead to additional research opportunities and change the outdated reputation of CBDs and marijuana.
The Future of the CBD Industry
With an abundance of recent studies and research regarding the medicinal marvels of CBDs, we hope that one day CBDs are completely removed from the DEA’s Controlled Substances Act. CBDs have no psychoactive effects alongside no negative symptoms when administered correctly. As more and more agencies and authoritative organizations start to recognize these medicinal benefits, the better regulated our industry will become.
For more information regarding CBD industry news or treatments for you and your loved ones, please contact us or call: 303-882-8920